Business Description
ChemoMetec AS
ISIN : DK0060055861
Total Employee Number:
172Compare
Compare
Traded in other countries / regions
CHEMM.Denmark0DZ0.UKCHY.Germany IPO Date
2025-10-21Description
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications includeĀ Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well asĀ image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 52.71 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 181.95 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 32.07 | |||||
Beneish M-Score | -2.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5 | |||||
3-Year EBITDA Growth Rate | 5.2 | |||||
3-Year EPS without NRI Growth Rate | 5.4 | |||||
3-Year FCF Growth Rate | 5.7 | |||||
3-Year Book Growth Rate | 23.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.27 | |||||
9-Day RSI | 60.7 | |||||
14-Day RSI | 59.67 | |||||
3-1 Month Momentum % | 20.8 | |||||
6-1 Month Momentum % | -9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.93 | |||||
Quick Ratio | 3.06 | |||||
Cash Ratio | 2.23 | |||||
Days Inventory | 1930.57 | |||||
Days Sales Outstanding | 63.59 | |||||
Days Payable | 266.61 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 95.54 | |||||
Operating Margin % | 46.86 | |||||
Net Margin % | 35.9 | |||||
EBITDA Margin % | 52.29 | |||||
FCF Margin % | 26.92 | |||||
OCF Margin % | 42.61 | |||||
ROE % | 27.6 | |||||
ROA % | 22.68 | |||||
ROIC % | 42.43 | |||||
3-Year ROIIC % | 12.41 | |||||
ROC (Joel Greenblatt) % | 119.3 | |||||
ROCE % | 35.4 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 42.28 | |||||
Forward PE Ratio | 28.43 | |||||
PE Ratio without NRI | 42.28 | |||||
Shiller PE Ratio | 78.29 | |||||
Price-to-Owner-Earnings | 46.62 | |||||
PEG Ratio | 2.15 | |||||
PS Ratio | 15.18 | |||||
PB Ratio | 11.47 | |||||
Price-to-Tangible-Book | 15.43 | |||||
Price-to-Free-Cash-Flow | 56.38 | |||||
Price-to-Operating-Cash-Flow | 35.63 | |||||
EV-to-EBIT | 31.37 | |||||
EV-to-EBITDA | 27.98 | |||||
EV-to-Revenue | 14.63 | |||||
EV-to-FCF | 54.34 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 4.02 | |||||
Price-to-DCF (Earnings Based) | 1.1 | |||||
Price-to-DCF (FCF Based) | 1.76 | |||||
Price-to-Median-PS-Value | 0.85 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.04 | |||||
Price-to-Graham-Number | 5.39 | |||||
| Price-to-Net-Current-Asset-Value | 21.19 | |||||
| Price-to-Net-Cash | 52.11 | |||||
Earnings Yield (Greenblatt) % | 3.19 | |||||
FCF Yield % | 1.77 | |||||
Forward Rate of Return (Yacktman) % | 20.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
ChemoMetec AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ā¬) | 66.06 | ||
| EPS (TTM) (ā¬) | 1.362 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 59.67 | ||
| 14-Day ATR (ā¬) | 1.033597 | ||
| 20-Day SMA (ā¬) | 55.1575 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (ā¬) | 33.08 - 104.6 | ||
| Shares Outstanding (Mil) | 17.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ChemoMetec AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ChemoMetec AS Stock Events
| Event | Date | Price (ā¬) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-04 | In 178 days | ||
| First quarter earnings results for 2027 | 2026-11-06 | In 88 days | ||
| General meeting for 2026 | 2026-10-08 | In 59 days | ||
| Annual report for 2026 | 2026-09-10 | In 31 days | ||
| Third quarter earnings results for 2026 | 2026-05-06 | 43.00 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-04 | 81.60 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-11-06 | -- | ||
| General meeting for 2025 | 2025-10-09 05:30 | -- | ||
| Annual report for 2025 | 2025-09-11 | -- | ||
| Third quarter earnings results for 2025 | 2025-05-07 | -- |
Show
Entries
ChemoMetec AS Frequently Asked Questions
What is ChemoMetec AS(HAM:CHY)'s stock price today?
The current price of HAM:CHY is ā¬56.80. The 52 week high of HAM:CHY is ā¬104.60 and 52 week low is ā¬33.08.
When is next earnings date of ChemoMetec AS(HAM:CHY)?
The next earnings date of ChemoMetec AS(HAM:CHY) is 2026-11-06 Est..
Does ChemoMetec AS(HAM:CHY) pay dividends? If so, how much?
ChemoMetec AS(HAM:CHY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ChemoMetec AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers